Introduction
============

Colorectal cancer (CRC) is a frequent malignant tumor in developed countries, with high morbidity and a high death rate. According to statistics published in 2015, CRC is the third most frequently diagnosed cancer in males and ranks second in females ([@b1-mmr-20-04-3583]). According to the American Joint Committee on Cancer, the 5-year overall survival (OS) rate of CRC is 65.2% ([@b2-mmr-20-04-3583]). Common risk factors for CRC include age, obesity, smoking and an unhealthy diet ([@b3-mmr-20-04-3583]). Previous studies have found that several patients present with unresectable stage disease at initial diagnosis ([@b4-mmr-20-04-3583],[@b5-mmr-20-04-3583]). Standard treatments for CRC include surgical resection, modern chemotherapy and radiation therapy. Although chemotherapy plays an important role in CRC treatment, the chemoresistance-reduced effectiveness of anti-neoplastic agents causes a lower survival rate of advanced-stage CRC patients.

Oxaliplatin (OxPt) is a third-generation platinum-based chemotherapeutic drug that inhibits the DNA replication and transcription of tumor cells ([@b6-mmr-20-04-3583]). When used in combination with fluorouracil (5-FU), leucovorin and folinic acid, it is recognized as the first-line chemotherapy strategy for CRC ([@b7-mmr-20-04-3583]). In recent years, the extensive use of OxPt has caused increased chemoresistance in clinical practice. Previous studies have found that the nucleotide excision repair pathway plays a key role in OxPt resistance ([@b8-mmr-20-04-3583],[@b9-mmr-20-04-3583]). Moreover, the overexpression of chemoresistance-associated proteins (e.g., transforming growth factor-β and WBSCR22) and microRNAs, and increased messenger RNA levels of XPAC and ERCC1, are believed to predict chemoresistance to OxPt ([@b10-mmr-20-04-3583]--[@b12-mmr-20-04-3583]).

Irinotecan, an analogue of camptothecin isolated from the Chinese tree *Camptotheca acuminata*, was first approved by the Food and Drug Administration for the treatment of CRC in 1996 and is now used as the second choice for CRC chemotherapy ([@b13-mmr-20-04-3583]). Irinotecan selectively inhibits topoisomerase I and induces the degradation of double-stranded DNA via intracellular modifications. Ultimately, irinotecan is activated by carboxylesterases to its active metabolite SN-38, which combines with topoisomerase and induces the breakage of DNA strands, DNA replication failure and cellular apoptosis ([@b14-mmr-20-04-3583],[@b15-mmr-20-04-3583]). The therapeutic efficacy and toxicity of irinotecan are related to the expression of tumor-specific genes and the intra-tumor accumulation of SN-38 ([@b16-mmr-20-04-3583]). Irinotecan treatment may also cause severe chemoresistance via variable levels of metabolic enzymes, reduced cellular accumulation from active drug efflux and reduced levels of Topo I expression, as well as different mutations and/or the activation of nuclear factor κB (NF-κB) ([@b17-mmr-20-04-3583]).

Long non-coding RNAs (lncRNAs), defined as mRNA-like transcripts with lengths up to 200 nucleotides, are important members of the non-coding RNA family ([@b18-mmr-20-04-3583]). lncRNA expression is regulated by both transcriptional and epigenetic factors. Several studies have revealed that lncRNAs are expressed in various tumor tissues and are involved in a number of cellular functions and developmental processes, such as cell growth, development, invasion, and apoptosis ([@b19-mmr-20-04-3583]--[@b21-mmr-20-04-3583]). Increasing lines of evidence suggest that lncRNAs are valuable bio-targets in the diagnosis and treatment of CRC ([@b22-mmr-20-04-3583]). Recent studies have suggested that lncRNAs play a key role in drug function regulation and chemoresistance through various mechanisms in multiple cancers ([@b23-mmr-20-04-3583],[@b24-mmr-20-04-3583]). At present, at least 70 CRC-related lncRNAs have been recognized, including HOTAIR, CCAT1, CCAT2, MALAT-1 and H19 ([@b25-mmr-20-04-3583]). Changes in the expression of these lncRNAs could lead to chemotherapy and radiotherapy resistance. Therefore, further research and efforts are needed to clarify the chemoresistance mechanism of each lncRNA. Then a simple and reliable screening program based on the expression levels of lncRNAs can be developed to guide the selection of chemotherapy drugs.

In the current study, previously published RNA expression datasets on the chemoresistance of CRC in the Gene Expression Omnibus (GEO) database were searched. A comprehensive bioinformatics analysis was performed by defining the differentially expressed lncRNAs and other RNAs separately according to their chemoresistance to irinotecan or OxPt. The differentially expressed lncRNAs were correlated with differentially expressed genes (DEGs) and potential diseases based on the RNA-associated interactions database (RAID) and the mammalian lncRNA-disease repository (MNDR) database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were also performed and a protein-protein interaction (PPI) network was established to screen for crucial genes and lncRNAs, whose hazard degrees were further demonstrated by evaluating their expression in tumors and according to tumor, node and metastasis (TNM) stage, as well as survival.

Materials and methods
=====================

### Datasets and DEG identification

Gene expression profiles for chemoresistance to two chemotherapeutic drugs, OxPt and irinotecan (active metabolite SN-38), in three CRC cell lines (HCT116, HT29, and LoVo) were obtained from GSE42387 in the GEO database ([@b26-mmr-20-04-3583]). Gene expression data were explored and visualized in the ggplot2 package of R software (version 3.2.0, <http://ggplot2.tidyverse.org>) for each sample in the nine groups (normal HCT116, OxPt-resistant HCT116, SN-38-resistant HCT116, normal HT29, OxPt-resistant HT29, SN-38-resistant HT29, normal LoVo, OxPt-resistant LoVo and SN-38-resistant LoVo). A detailed workflow of the data analysis is shown in [Fig. S1](#SD1-mmr-20-04-3583){ref-type="supplementary-material"}. The limma package, which includes lmFit, eBayes and top Table functions, was used for the pairwise comparison of DEGs among the nine groups ([@b27-mmr-20-04-3583]). The cutoff criteria were P\<0.05 and abs(log~2~FC)\>1, where FC indicates fold-change. The screened DEGs were divided into two groups, differentially expressed mRNAs and lncRNAs, which were further analyzed.

### GO annotation and KEGG pathway enrichment analyses of DEGs

As mentioned above, two groups of DEGs: mRNAs and lncRNAs were analyzed. Based on RAID version 2.0 ([@b28-mmr-20-04-3583]), the potential targets (confidence score \>0.5) of the differentially expressed lncRNAs were obtained and intersected with DEGs found in the same group. Next, the intersected DEGs were divided into two groups: OxPt resistance and irinotecan resistance. GO annotation is a classic method used to identify the biological attributes of DEGs. This analysis comprises three parts: Biological process (BP), cell component (CC) and molecular function (MF). KEGG, a collection of genome, biological pathway, disease, drug and chemical substance databases, was used to identify the functional attributes of the DEGs. The Database for Annotation, Visualization and Integrated Discovery (DAVID; ver. 6.8) ([@b29-mmr-20-04-3583],[@b30-mmr-20-04-3583]) was also applied for the functional interpretation of the two large lists of genes derived from previous analyses. Statistical significance was set at P\<0.05.

### PPI network construction and hub gene identification

A PPI network was constructed for the DEGs using STRING ([@b31-mmr-20-04-3583]), an online functional protein association network tool, to detect potential relationships among the DEGs with confidence scores ≥0.4 and a maximum number of interactors of 1. The generated PPI network data were downloaded and imported into Cytoscape software (ver. 3.5.1), a bioinformatics tool used to create networks of protein interactions and reassess and integrate gene information from numerous embedded applications. The CentiScaPe plugin was used to determine the characteristics of each node in the PPI network, which gave each gene a degree score, the simplest topological index, allowing for immediate evaluation of the average number of edges (interactions) incident to the node ([@b32-mmr-20-04-3583]). Genes with a degree ≥5 in significantly perturbed networks were defined as hub genes (mRNA). The differentially expressed lncRNA-mRNA interaction network was constructed and displayed by Cytoscape (version 3.5, <http://www.cytoscape.org/>). The lncRNA holding interactions with the greatest number of hub genes (mRNA) in the network were defined as hub lncRNAs.

### Constructing the differentially expressed lncRNA-related disease network

Each lncRNA has a disease association profile. According to MNDR version 2.0 ([@b33-mmr-20-04-3583]), a global view of the lncRNA-mediated disease network, which contains all of the differentially expressed lncRNA-related disease data (confidence score \>0.5), was downloaded and integrated by R software. The disease network was constructed by Cytoscape. The disease label size was normalized to the number of lncRNAs related to each disease.

### Hub lncRNA analysis

The hub lncRNAs were further investigated using Gene Expression Profiling Interactive Analysis, a newly developed interactive web server for analyzing the RNA sequencing expression data of 9,736 tumors and 8,587 normal samples from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression projects ([@b34-mmr-20-04-3583]). The expression of each hub lncRNA in colon adenocarcinoma and rectum adenocarcinoma was compared with in normal tissue and to different tumor stages and plotted. Survival analysis was performed based on information from TCGA database. Relapse-free survival and OS were calculated. Hazard ratios with 95% confidence intervals and P-values calculated based on the Mantel-Cox log-rank test are displayed in Kaplan-Meier plots.

Results
=======

### Data quality control and DEG screening

A total of 32,705 genes were detected in each sample; their expression values and data distributions were similar between groups ([Fig. S2A](#SD1-mmr-20-04-3583){ref-type="supplementary-material"}) and among samples ([Fig. S2B](#SD1-mmr-20-04-3583){ref-type="supplementary-material"}). Principal component analysis showed that samples were easily grouped in different cell lines but not into certain drug resistance patterns ([Fig. S2C](#SD1-mmr-20-04-3583){ref-type="supplementary-material"}). Therefore, further bioinformatics analysis should be performed separately based on different cell lines and chemoresistance. This dataset qualified for the following analysis.

Following data processing using limma, 255 DEGs in HCT116-OxPt vs. HCT116, 672 DEGs in HT29-OxPt vs. HT29, 491 DEGs in LoVo-OxPt vs. LoVo, 283 DEGs in HCT116-SN-38 vs. HCT116, 779 DEGs in HT29-SN-38 vs. HT29 and 1,713 DEGs in LoVo-SN-38 vs. LoVo were identified ([Fig. S2D and E](#SD1-mmr-20-04-3583){ref-type="supplementary-material"}). The detailed DEGs information were shown in [Tables SI](#SD1-mmr-20-04-3583){ref-type="supplementary-material"}--[SVI](#SD1-mmr-20-04-3583){ref-type="supplementary-material"}.

### Intersection between the predicted targets of lncRNAs and DEGs

Among all of the DEGs identified in each comparison, the differentially expressed lncRNAs were isolated and are listed in [Table I](#tI-mmr-20-04-3583){ref-type="table"}. The target prediction of each lncRNA was searched and obtained using RAID version 2.0. Next, the target genes were intersected with the identified DEGs in each comparison and are displayed as Venn diagrams ([Fig. 1A](#f1-mmr-20-04-3583){ref-type="fig"}). The intersected DEGs in the same drug management were united to perform GO annotation and KEGG pathway enrichment analyses based on DAVID. All significant (P\<0.05) enriched entries in OxPt resistance are shown in a histogram ([Fig. 1B](#f1-mmr-20-04-3583){ref-type="fig"}), with the top three being protein ubiquitination, SMAD protein signal transduction and negative regulation of protein kinase activity in the BP GO annotation category; extracellular exosome and focal adhesion in the CC category; and GTP binding, receptor binding, and calmodulin binding in the MF category. All significant (P\<0.05) enriched entries in irinotecan resistance are also shown in a histogram ([Fig. 1C and D](#f1-mmr-20-04-3583){ref-type="fig"}), with the top three being positive regulation of transcription from RNA polymerase II promoter, positive regulation of apoptotic process, angiogenesis in the BP GO annotation category; cytoplasm, extracellular exosome, and extracellular space in the CC category; protein homodimerization activity, RNA polymerase II core promoter proximal region sequence-specific DNA binding, and growth factor activity in the MF category; and pathways in cancer, microRNAs in cancer, and TNF signaling pathway in the KEGG pathway. Detailed information on the DEGs involved in the BP GO category and KEGG pathway are listed in [Fig. 1E](#f1-mmr-20-04-3583){ref-type="fig"}.

### Identification of hub lncRNAs and their associated disease network

There was a positive association between mRNA and protein expression changes; therefore, putative PPI network maps were constructed for the united datasets of chemoresistance using the STRING database and Cytoscape. Excluding the DEGs distributed on the edge of the PPI network, the remaining 26 and 57 central DEGs in the OxPt and SN-38 groups, respectively, were evaluated using the CentiScaPe plugin. The degree index of each central DEG was calculated and hub genes were defined using the criterion that the degree value must be ≥5. In the OxPt group, the hub genes were FOS, VIM, PLAUR and IGF2. In the SN-38 group, the hub genes were VEGFA, JUN, PTGS2, FOS, VIM, STAT1, CDKN1A, MMP3, CCL5, LYN, ATF3, KITLG, MMP1, FN1, CEBPB, CXCL2, MUC1, CRYZ, WNT5A and FOXA2 ([Tables SVII](#SD1-mmr-20-04-3583){ref-type="supplementary-material"} and [SVIII](#SD1-mmr-20-04-3583){ref-type="supplementary-material"}). These hub genes are marked in red in the PPI network ([Figs. 2A](#f2-mmr-20-04-3583){ref-type="fig"} and [3A](#f3-mmr-20-04-3583){ref-type="fig"}). In a similar manner, the interaction network between each specific lncRNA and its potential targets in DEGs were visualized using Cytoscape in [Figs. 2B](#f2-mmr-20-04-3583){ref-type="fig"} and [3B](#f3-mmr-20-04-3583){ref-type="fig"}. Up- and downregulated DEGs are colored in red and blue, respectively. The log~2~FC value is also indicated by the size of the node. Each hub lncRNA was identified by calculating its downstream hub genes whose count should be ranked in the top three and larger than 2. During OxPt screening, the lncRNAs CRNDE (target DEGs: PLAUR and FOS) and H19 (target DEGs: IGF2 and VIM) stood out. SN-38 screening revealed the following lncRNAs: CRNDE (target DEGs: STAT1, MUC1, LYN, KITLG, CXCL2, CRYZ, CCL5 and ATF3), HOTAIR (target DEGs: VEGFA, CDKN1A, VIM, MMP3, and MMP1), and UCA1 (target DEGs: CDKN1A, JUN, WNT5A, PTGS2, and FN1).

Information on lncRNA-associated diseases was obtained in full scale according to the MNDR database. By integrating this information in Cytoscape, the major related diseases associated with the differentially expressed lncRNAs were clearly sorted out. The more lncRNAs a disease is connected to, the larger its label. As shown in [Fig. 4](#f4-mmr-20-04-3583){ref-type="fig"}, cancer is the word that most frequently appears. Among them, CRC is obvious in the OxPt-lncRNA-related disease network, which is strongly connected to CRNDE and H19 ([Fig. 4A](#f4-mmr-20-04-3583){ref-type="fig"}), whereas the SN-38-lncRNA-related disease network is strongly connected to GAS5, UCA1, NEAT1, and CRNDE ([Fig. 4B](#f4-mmr-20-04-3583){ref-type="fig"}).

### lncRNA expression validation and survival analysis in TCGA

TCGA database was utilized to validate and compare hub lncRNA expression in tumor and normal tissues. Although the results cannot relate the expression levels of these lncRNAs to chemoresistance, it did, to a certain extent, partially confirm the hazard degree of each lncRNA. As indicated in [Fig. 5A-D](#f5-mmr-20-04-3583){ref-type="fig"}, the expression of CRNDE and UCA1 was significantly increased in tumor tissue compared with in normal tissue (P\<0.05). Except for CRNDE, the expression of three other lncRNAs increased as the TNM stage increased. In [Fig. 5E-H](#f5-mmr-20-04-3583){ref-type="fig"}, only HOTAIR showed a significant relationship with OS and disease-free survival (DFS; P\<0.05). Patients with increased expression of HOTAIR suffered a shorter OS (HR=1.9, P=0.0066) and DFS (HR=1.8, P=0.012) compared to those with weaker expression.

Discussion
==========

In recent years, the prevalence of CRC has increased worldwide. Due to the popularity of prophylactic screening, CRC can be diagnosed and treated increasingly early ([@b3-mmr-20-04-3583]). However, many patients are in late stages when diagnosed (≥stage III or high-risk stage II) and require neoadjuvant or adjuvant chemotherapy ([@b7-mmr-20-04-3583]). Some patients must face a tough reality-chemoresistance-which results in a shorter survival owing to limited chemotherapy choices. Although a previous bioinformatics analysis has revealed differences in gene expression patterns in chemoresistant cells, such as original study of GSE42387 done by Jensen *et al* ([@b26-mmr-20-04-3583]), few have determined pivotal lncRNAs involved in this process. Therefore, a comprehensive analysis at the whole-genome level is necessary to identify key lncRNAs and provide detailed gene signatures for effective chemotherapy. The present study aimed at exploring the relationship between aberrant expressed lncRNAs and mRNAs. The GEO dataset was re-analyzed by relaxing DEG screening condition to gain more information. Only DEGs predicted to be the targets of differential expressed lncRNAs were involved in the following analysis.

To gain further insight into the biological pathways and identify key factors involved in chemoresistance, functional analyses of lncRNA-targeted DEGs, including GO annotation and KEGG pathway enrichment analyses were performed. The present study found that several DEGs are components of the extracellular exosome. Interestingly, the exosome is believed to confer chemoresistance to pancreatic cancer ([@b35-mmr-20-04-3583]), breast cancer ([@b36-mmr-20-04-3583]), gastric cancer ([@b37-mmr-20-04-3583]) and CRC ([@b38-mmr-20-04-3583]). It is believed that due to their cell-to-cell communication, exosomes protect tumor cells from the cytotoxic effects of chemotherapy drugs and transfer chemoresistance properties to nearby cells ([@b39-mmr-20-04-3583]). The items enriched in GO biological processes indicate that chemoresistance occurring during both OxPt and irinotecan therapy is associated with an imbalance between cell proliferation and apoptosis regulation, cell energetic metabolism under hypoxic conditions, and angiogenesis. However, it seems that irinotecan treatment yields more DEGs than OxPt treatment. The present study hypothesized that this is why OxPt is the first choice for the clinical therapy of CRC.

In the present study, four hub lncRNAs were identified: CRNDE, H19, UCA1 and HOTAIR. CRNDE is a 1,910-nt cancer-secreted lncRNA transcribed by human chromosome 16 (16q12.2). Decades of research have shown that the high expression of CRNDE is involved in the progression of several cancers, such as renal cell carcinoma ([@b40-mmr-20-04-3583]), hepatocellular carcinoma ([@b41-mmr-20-04-3583]) and glioma tumors ([@b42-mmr-20-04-3583]). Liu *et al* ([@b43-mmr-20-04-3583]) found exosomal CRNDE-h in the sera of CRC patients. They also found a positive correlation between serum levels of CRNDE-h and regional lymph node or distant metastasis. Therefore, they believe that exosomal CRNDE can be used as a serum biochemical marker in the diagnosis and prognosis of CRC. Another recent study revealed that the overexpression of CRNDE promoted the development of CRC by suppressing the expression of dual-specificity phosphatase 5 (DUSP5) and CDKN1A. Moreover, the knockdown of CRNDE significantly blocked cell proliferation and induced apoptosis ([@b44-mmr-20-04-3583]). In glioma, CRNDE promoted cell growth and invasion via mTOR signaling ([@b42-mmr-20-04-3583]). The involvement of CRNDE in the chemoresistance of CRC treatment has also been assessed by a number of researchers ([@b45-mmr-20-04-3583],[@b46-mmr-20-04-3583]). After treating CRC cells with different concentrations of 5-FU, Han *et al* ([@b45-mmr-20-04-3583]) found that CRNDE-knockdown CRC cells exhibited increased sensitivity to 5-FU and OxPt treatment. Together, these results suggest that CRNDE is closely related to the development and chemoresistance of CRC.

Another hub lncRNA identified in the present study, lncRNA H19, is a key oncogenic mediator coded by chromosome 11. According to previous studies, H19 is overexpressed in various cancers, including breast cancer ([@b47-mmr-20-04-3583]), thyroid carcinoma ([@b48-mmr-20-04-3583]) and lung cancer ([@b49-mmr-20-04-3583]). H19 also plays an oncogenic role in the development of CRC. The expression of H19 is increased in CRC tissues from advanced TNM stage patients ([@b50-mmr-20-04-3583]). Enhanced H19 expression was also found in a CRC cell line and treatment with H19 significantly induced the proliferation of CRC cells, suggesting an underlying relationship between H19 and colorectal carcinogenesis ([@b51-mmr-20-04-3583]). H19 also plays an important role in the migration and invasion of CRC cells ([@b52-mmr-20-04-3583]). Increasing research attention has been given to the chemoresistance of H19 in the treatment of cancer ([@b53-mmr-20-04-3583],[@b54-mmr-20-04-3583]). Emerging evidence also indicates that H19 knockout in the HT-29 cell line (MTX-resistant colorectal cells) reduces the risk of drug resistance. Further investigations showed that this H19-related chemoresistance is mediated by the Wnt/β-catenin signaling pathway ([@b55-mmr-20-04-3583]).

HOTAIR is a novel oncogenic lncRNA transcribed by the HoxC gene. As with the abovementioned lncRNAs, HOTAIR has also been identified in several cancers, including osteosarcoma ([@b56-mmr-20-04-3583]), cervical cancer ([@b57-mmr-20-04-3583]) and gastric cancer ([@b58-mmr-20-04-3583]). Similarly, HOTAIR exerts its oncogenic role by regulating CRC cell proliferation, invasion, and migration by mediating p21 ([@b59-mmr-20-04-3583]). Elevated HOTAIR expression has also been detected in CRC cells and tissues relative to adjacent control tissues ([@b60-mmr-20-04-3583],[@b61-mmr-20-04-3583]). The precise role of HOTAIR in chemoresistance in the chemotherapy of CRC was also recently reported. Li *et al* ([@b62-mmr-20-04-3583]) indicated that HOTAIR promotes the chemoresistance of CRC cells to 5-FU by suppressing miR-218 and activating NF-κB signaling. Another study performed by Xiao *et al* ([@b63-mmr-20-04-3583]) found that HOTAIR knockout improved the sensitivity of CRC cells to cisplatin and paclitaxel and that this mechanism may, at least in part, be related to the expression of miR-203a-3p and activation of the Wnt/β-catenin signaling pathway.

The regulatory role of UCA1 in chemotherapy drug resistance in CRC was also investigated. The upregulated lncRNA UCA1 is correlated with the progression of lung cancer, esophageal squamous cell carcinoma and CRC ([@b64-mmr-20-04-3583]--[@b66-mmr-20-04-3583]) and predicts a poor prognosis. Compared with control tissues, an increased level of UCA1 was found in CRC tissues and cells and the level of UCA1 was positively correlated with tumor size and depth ([@b67-mmr-20-04-3583]). Further *in vitro* experiments suggested that UCA1 induces CRC cell proliferation and inhibits apoptosis. Recent studies have also revealed the potential role of UCA1 in chemoresistance in CRC. CRC cells with UCA1 knockdown exhibit sensitivity to 5-FU by increasing tumor cell apoptosis. Conversely, UCA1 overexpression may result in increased resistance to 5-FU treatment, suggesting that UCA1 may predict the response to CRC chemotherapy ([@b68-mmr-20-04-3583]). Furthermore, overexpression of UCA1 has a consanguineous connection with radioresistance in CRC treatment ([@b69-mmr-20-04-3583]).

Collectively, the current study identified four pivotal lncRNAs, CRNDE, H19, UCA1 and HOTAIR, which are strongly associated with CRC chemoresistance and can be used as predictive factors for treatment sensitivity and tumor prognosis. Functional enrichment analysis indicated that an imbalance between cell proliferation and apoptosis, cell energetic metabolism under hypoxic conditions, and angiogenesis were the key biological processes whereby lncRNAs perturbed gene expression and altered sensitivity of tumor cells to chemotherapy. However, the results of the present study are based entirely on bioinformatics analyses and lack *in vivo* and *in vitro* experimental evidence. Further research is required to delineate their potential roles in chemoresistance.
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###### 

Functional analyses of differentially expressed long non-coding RNA lncRNA-targeted DEGs. (A) A Venn diagram between lncRNA target genes in the database and screened DEGs for the six comparison groups. Histograms of GO functional classification of DEGs for the (B) OxPt resistance group and the (C) SN-38 resistance group. The x-axis represents the number of DEGs and the y-axis represents the GO terms. All GO terms were grouped into three ontologies: Biological process, cellular component and molecular function. The graph displays only significantly enriched GO terms (P\<0.05); darker blue indicates greater significance. (D) A histogram of the KEGG pathway enrichment of DEGs screened in the SN-38 resistance group, where the x-axis represents the number of DEGs annotated in a pathway term; enriched pathways are shown on the y-axis. The graph displays only significantly enriched KEGG terms (P\<0.05); darker red indicates greater significance. (E) A table listing biological process GO and KEGG terms in each group. lncRNA, long non-coding RNA; GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DEG, differentially expressed genes.
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![PPI network construction for the OxPt resistance group. (A) PPI network for screened lncRNA-targeted DEGs. Genes marked in red represent hub genes with a degree ≥5 (color and size are increased along with degree value). The darker the connection line, the greater the confidence score. (B) lncRNA-mRNA association network. Circles indicate mRNAs and diamonds indicate non-protein-coding RNAs. A larger node indicates a larger log~2~FC value. Upregulated genes are shown in pink and downregulated genes are shown in blue. PPI, protein-protein interaction; lncRNA, long noncoding RNA; OxPt, oxaliplatin; DEG, differentially expressed genes; FC, fold-change.](MMR-20-04-3583-g02){#f2-mmr-20-04-3583}

![PPI network construction for the SN-38 resistance group. (A) PPI network for screened lncRNA-targeted DEGs. Genes marked in red represent hub genes with a degree ≥5 (color and size are increased along with degree value). The darker the connection line, the greater the confidence score. (B) lncRNA-mRNA association network. Circles indicate mRNAs and diamonds indicate non-protein-coding RNAs. A larger node indicates a larger log~2~fold-change value. Upregulated genes are shown in pink and downregulated genes are shown in blue. PPI, protein-protein interaction; lncRNA, long noncoding RNA; DEG, differentially expressed genes.](MMR-20-04-3583-g03){#f3-mmr-20-04-3583}

![lncRNA-related disease network construction. (A) The OxPt resistance group and (B) the SN-38 resistance group. lncRNAs are indicated in red circles. Diseases are indicated in blue square. The disease label size is normalized to the number of lncRNAs related to each disease. Lnc, long noncoding; OxPt, oxaliplatin.](MMR-20-04-3583-g04){#f4-mmr-20-04-3583}
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Clinical significances of hub lncRNAs. Analyses of hub lncRNAs expression in tumor vs. normal tissues and in different tumor stages for (A) CRNDE, (B) H19, (C) HOTAIR, and (D) UCA1. The red box stands for tumor tissue; grey box is for normal tissue; and dots presents each sample value in left panel. \*P\<0.05; other P-values are shown on the diagrams. Overall and disease-free survival analyses of hub lncRNAs (E) CRNDE, (F) H19, (G) HOTAIR, and (H) UCA1. P-values are shown on the diagrams. READ, rectum adenocarcinoma; COAD, colon adenocarcinoma
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###### 

Drug resistance-related differentially expressed non-coding RNAs.

  Group         ID          Symbol                                                   logFC   AveExpr   P-value       Change   Gene name
  ------------- ----------- -------------------------------------------------------- ------- --------- ------------- -------- ------------------------------------------------
  HCT116-OxPt   285735      LINC00326                                                1.46    7.31      2.1×10^−05^   UP       Long intergenic non-protein coding RNA 326
                284739      LINC00176                                                1.11    8.93      1.3×10^−02^   UP       Long intergenic non-protein coding RNA 176
  HT29-OxPt     283460      HNF1A-AS1                                                −1.72   7.65      5.0×10^−05^   DOWN     HNF1A antisense RNA 1
                643911      CRNDE^[a](#tfn1-mmr-20-04-3583){ref-type="table-fn"}^    −1.97   10.82     1.4×10^−06^   DOWN     Colorectal neoplasia differentially expressed
  LoVo-OxPt     283120      H19^[a](#tfn1-mmr-20-04-3583){ref-type="table-fn"}^      1.00    7.06      5.4×10^−04^   UP       H19, imprinted maternally expressed transcript
                64150       DIO3OS                                                   −1.79   8.51      2.5×10^−06^   DOWN     DIO3 opposite strand/antisense RNA
                196047      EMX2OS                                                   −1.46   7.87      2.5×10^−03^   DOWN     EMX2 opposite strand/antisense RNA
  HCT116-SN38   652995      UCA1^[a](#tfn1-mmr-20-04-3583){ref-type="table-fn"}^     −1.40   12.29     4.4×10^−06^   DOWN     Urothelial cancer associated 1
  HT29-SN38     441951      ZNFX1-AS1                                                1.35    10.22     9.2×10^−05^   UP       ZNFX1 antisense RNA 1
                727701      LINC00165                                                −1.03   7.43      5.5×10^−05^   DOWN     Long intergenic non-protein coding RNA 165
                100169750   PRINS                                                    −1.50   9.81      6.8×10^−06^   DOWN     Psoriasis associated RNA induced by stress
                283460      HNF1A-AS1                                                −1.62   7.70      6.6×10^−05^   DOWN     HNF1A antisense RNA 1
                554202      MIR31HG                                                  −1.49   8.07      1.3×10^−05^   DOWN     MIR31 host gene
                283131      NEAT1                                                    1.32    11.22     9.3×10^−04^   UP       Nuclear paraspeckle assembly transcript 1
                100289410   MCF2L-AS1                                                −1.30   9.95      2.8×10^−06^   DOWN     MCF2L antisense RNA 1
                643911      CRNDE^[a](#tfn1-mmr-20-04-3583){ref-type="table-fn"}^    −1.17   11.21     2.9×10^−05^   DOWN     Colorectal neoplasia differentially expressed
  LoVo-SN38     100093630   SNHG8                                                    −1.49   9.80      1.3×10^−03^   DOWN     Small nucleolar RNA host gene 8
                253264      ZNF503-AS1                                               −2.28   7.90      8.6×10^−07^   DOWN     ZNF503 antisense RNA 1
                60674       GAS5                                                     −1.21   15.21     2.1×10^−02^   DOWN     Growth arrest-specific 5
                64150       DIO3OS                                                   1.07    9.94      4.0×10^−05^   UP       DIO3 opposite strand/antisense RNA
                196047      EMX2OS                                                   −1.10   8.05      8.5×10^−03^   DOWN     EMX2 opposite strand/antisense RNA
                128439      SNHG11                                                   −1.39   10.12     4.7×10^−04^   DOWN     Small nucleolar RNA host gene 11
                100124700   HOTAIR^[a](#tfn1-mmr-20-04-3583){ref-type="table-fn"}^   1.58    7.21      3.1×10^−06^   UP       HOX transcript antisense RNA
                114915      EPB41L4A-AS1                                             −1.42   15.27     3.0×10^−02^   DOWN     EPB41L4A antisense RNA 1
                652995      UCA1^[a](#tfn1-mmr-20-04-3583){ref-type="table-fn"}^     −1.45   7.58      1.6×10^−04^   DOWN     Urothelial cancer associated 1
                401237      LINC00340                                                1.99    7.58      1.7×10^−06^   UP       Long intergenic non-protein coding RNA 340
                29092       LINC00339                                                −1.55   9.20      4.0×10^−03^   DOWN     Long intergenic non-protein coding RNA 339
                79992       AGPAT4-IT1                                               1.50    8.13      2.5×10^−04^   UP       AGPAT4 intronic transcript 1
                388815      LINC00478                                                3.03    8.11      2.7×10^−08^   UP       Long intergenic non-protein coding RNA 478

Hub ncRNA. OxPt, oxaliplatin; nc, noncoding.
